ATE541038T1 - Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten - Google Patents

Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten

Info

Publication number
ATE541038T1
ATE541038T1 AT07799710T AT07799710T ATE541038T1 AT E541038 T1 ATE541038 T1 AT E541038T1 AT 07799710 T AT07799710 T AT 07799710T AT 07799710 T AT07799710 T AT 07799710T AT E541038 T1 ATE541038 T1 AT E541038T1
Authority
AT
Austria
Prior art keywords
aggregates
protein
peptide
inclusions
treatment
Prior art date
Application number
AT07799710T
Other languages
English (en)
Inventor
Beka Solomon
Noa Sharon
Oded Grinstein
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE541038T1 publication Critical patent/ATE541038T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT07799710T 2006-07-21 2007-07-19 Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten ATE541038T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83222906P 2006-07-21 2006-07-21
PCT/US2007/073858 WO2008011503A2 (en) 2006-07-21 2007-07-19 Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates

Publications (1)

Publication Number Publication Date
ATE541038T1 true ATE541038T1 (de) 2012-01-15

Family

ID=38957610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07799710T ATE541038T1 (de) 2006-07-21 2007-07-19 Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten

Country Status (8)

Country Link
US (1) US20090324554A1 (de)
EP (1) EP2054515B1 (de)
JP (1) JP2009544718A (de)
CN (1) CN101553567A (de)
AT (1) ATE541038T1 (de)
AU (1) AU2007275258A1 (de)
CA (1) CA2659032A1 (de)
WO (1) WO2008011503A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214632B2 (ja) * 2007-12-04 2013-06-19 サッポロビール株式会社 骨吸収抑制剤
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
AU2009316326A1 (en) * 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2696678B1 (de) * 2011-04-15 2019-11-20 Molecular Transfer, Inc. Mittel zur verbesserten verabreichung von nukleinsäuren in eukaryotische zellen
EP2736522A1 (de) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Verfahren zur herstellung von filamentösen bakteriophagen
HK1198627A1 (zh) 2011-08-05 2015-05-22 Neurophage Pharmaceuticals, Inc. 纯丝状噬菌体及其制备方法
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
CN104258372B (zh) * 2014-09-25 2017-01-25 中山大学 Rgd三肽在制备治疗阿尔茨海默症药物中的用途
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드
CN106800590B (zh) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用
EP4733313A3 (de) * 2017-05-22 2026-07-01 ResQ Biotech P.C. Makrocyclische modulatoren von krankheitsassoziierter proteinfehlfaltung und aggregation
CA3076473A1 (en) * 2017-09-20 2019-03-28 Council Of Scientific And Industrial Research Novel peptide as potent inhibitor of protein aggregation
WO2022073127A1 (en) * 2020-10-07 2022-04-14 Tatum Bioscience Inc. Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
IL163812A0 (en) * 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
WO2006050041A2 (en) * 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
JP5096169B2 (ja) * 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
WO2006100681A2 (en) * 2005-03-25 2006-09-28 Ramot At Tel Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Also Published As

Publication number Publication date
JP2009544718A (ja) 2009-12-17
WO2008011503A3 (en) 2008-06-26
EP2054515A2 (de) 2009-05-06
EP2054515B1 (de) 2012-01-11
US20090324554A1 (en) 2009-12-31
WO2008011503A2 (en) 2008-01-24
AU2007275258A1 (en) 2008-01-24
CN101553567A (zh) 2009-10-07
CA2659032A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008011503A3 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
Chen et al. Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
Gillrie et al. Diverse functional outcomes of P lasmodium falciparum ligation of EPCR: potential implications for malarial pathogenesis
Demidova‐Rice et al. Bioactive peptides derived from vascular endothelial cell extracellular matrices promote microvascular morphogenesis and wound healing in vitro
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
Metz et al. Elasmoid scales of fishes as model in biomedical bone research
PE20071055A1 (es) Anticuerpos anti mn
AR062065A1 (es) Anticuerpo humanizado
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
EP2532365A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EA201890907A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
NZ577274A (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EA201390820A1 (ru) Слитый белок против рака
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
Cameron et al. A novel murine model of hypertrophic scarring using subcutaneous infusion of bleomycin
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
EA201391453A1 (ru) Новое антитело против рецептора il-23 человека
MY160435A (en) A novel antiviral peptide against avian influenza virus h9n2